SCHEMBL5762030

SCHEMBL5762030

NC(=O)C(c1ccc2ccccc2c1)C1(O)CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.42
SLC6A2 P23975 3/20 0.40
SLC6A4 P31645 3/20 0.40
SLC6A3 Q01959 3/20 0.40
UGT2B7 P16662 1/20 0.39
TNF P01375 1/20 0.39
CHRM2 P08172 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
CHRM4 P08173 1/20 0.38
MAPT P10636 1/20 0.38
LMNA P02545 2/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3960336 0.87 CHRM2 (0.41) SLC6A2SLC6A4SLC6A3UGT2B7CHRM2
SCHEMBL3954493 0.82 UGT2B7 (0.41) SLC6A2SLC6A4SLC6A3UGT2B7CHRM2
SCHEMBL10806353 0.82 LMNA (0.52) EPHX1SLC6A2SLC6A4SLC6A3CHRM2
SCHEMBL28760855 0.81 CHRM2 (0.36) SLC6A2SLC6A4SLC6A3UGT2B7CHRM2
SCHEMBL10808122 0.80 LMNA (0.54) EPHX1CHRM2CHRM1CHRM3CHRM4
SCHEMBL809114 0.79 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3UGT2B7MAPT
SCHEMBL809201 0.79 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3UGT2B7MAPT
SCHEMBL809202 0.79 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3UGT2B7MAPT
SCHEMBL809113 0.79 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3UGT2B7MAPT
SCHEMBL27656082 0.78 LMNA (0.41) SLC6A2SLC6A4SLC6A3CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1972920-A Arylalkyl piperazine derivatives for the treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms WYETH CORP (US) 2007-05-30 CN disclosed
EP-1673084-A1 1-2' (1,4'-BIPERIDIN-1'-YL)-1-(PHENYL)-ETHYLCYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS Wyeth (US) 2006-06-28 EP disclosed
EP-1673090-A1 FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE Wyeth (US) 2006-06-28 EP disclosed
WO-2005037279-A1 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS WYETH (US) 2005-04-28 WO disclosed
WO-2005037283-A1 FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2005-04-28 WO disclosed